Peptides for sleep disorders

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Peptides for Sleep Disorders: Restoring Circadian Rhythms and Promoting Restorative Sleep Sleep disorders, affecting up to 70 million Americans, encompass a range of conditions from insomnia and sleep apnea to restless legs syndrome and circadian ...

Peptides for Sleep Disorders: Restoring Circadian Rhythms and Promoting Restorative Sleep

Sleep disorders, affecting up to 70 million Americans, encompass a range of conditions from insomnia and sleep apnea to restless legs syndrome and circadian rhythm disruptions, all significantly impacting physical and mental health [1]. These conditions significantly impair quality of life, increase the risk of chronic diseases, and reduce productivity. While conventional treatments often involve lifestyle modifications, continuous positive airway pressure (CPAP) for sleep apnea, or stimulant/hypnotic medications, many individuals experience suboptimal outcomes or side effects. Peptides offer a targeted approach by modulating the intricate neurochemical systems that govern sleep-wake cycles and overall sleep architecture.

The neurobiology of sleep is intricately regulated by a complex interplay of wake-promoting and sleep-promoting neurotransmitters and neuropeptides. Key players include adenosine, GABA, and melatonin for sleep induction, and orexin (hypocretin), histamine, and norepinephrine for maintaining wakefulness [2]. Dysregulation in these systems can lead to various sleep disorders. For instance, a deficiency in orexin is a hallmark of narcolepsy type 1, while an imbalance in sleep-promoting signals contributes to insomnia. Peptides can interact with these systems to restore physiological balance, promoting a more natural and sustainable return to healthy sleep patterns.

Delta Sleep-Inducing Peptide (DSIP) is a nonapeptide that has been studied for its somnogenic properties, particularly in promoting deep, restorative sleep. Administered intravenously, DSIP has been shown to increase delta-wave activity in the electroencephalogram (EEG), a marker of slow-wave sleep, and improve sleep efficiency in individuals with chronic insomnia [3]. While not a direct treatment for all sleep disorders, its ability to enhance the quality of deep sleep can be beneficial across various conditions where sleep fragmentation is an issue. Clinically, DSIP has been explored at doses ranging from 10-20 mcg/kg administered intravenously, often in short courses of 7-10 days. You'll find that DSIP primarily aims to deepen the quality of sleep rather than simply inducing sedation, promoting a more natural and restful state by modulating central nervous system activity to favor sleep onset and maintenance.

Orexin receptor antagonists (ORAs) represent a significant advancement in the treatment of insomnia and, by extension, other sleep disorders characterized by hyperarousal. Orexin, a wake-promoting neuropeptide, is overactive in many forms of insomnia. ORAs, such as suvorexant (Belsomra), daridorexant (Quviviq), and lemborexant (Dayvigo), work by blocking the action of orexin, thereby dampening the wakefulness signal and promoting sleep onset and maintenance [4]. For example, suvorexant is typically prescribed at 10-20 mg orally once nightly, 30 minutes before bedtime. This mechanism is particularly relevant for narcolepsy type 1, where a loss of orexin neurons leads to excessive daytime sleepiness and cataplexy. You'll observe that ORAs offer a distinct mechanism from traditional GABAergic hypnotics, which broadly suppress brain activity, by specifically targeting the wake-promoting system, leading to more natural sleep architecture and reduced next-day grogginess. This targeted approach minimizes the risk of dependence and preserves the natural sleep stages.

Melanin-Concentrating Hormone (MCH) is another neuropeptide involved in sleep regulation, primarily promoting REM sleep. MCH neurons are active during REM sleep and their activation can increase REM sleep duration [5]. While MCH receptor antagonists are being investigated for their potential in treating insomnia by reducing REM sleep fragmentation, research is still in earlier stages compared to ORAs. The intricate interplay between MCH and orexin systems is crucial for maintaining the balance between different sleep stages and wakefulness, and dysregulation can contribute to various sleep disorders. You'll find that understanding these complex interactions allows for more precise therapeutic targeting, potentially leading to treatments that optimize specific sleep stages and improve overall sleep quality.

BPC-157, a stable gastric pentadecapeptide, is primarily recognized for its regenerative and cytoprotective properties. While direct clinical trials for BPC-157 in primary sleep disorders are limited, its neuroprotective, anti-inflammatory, and gut-brain axis modulating effects could indirectly support sleep quality by reducing pain, anxiety, and inflammation—common contributors to sleep disturbances [6]. For example, by stabilizing the gut microbiome and reducing systemic inflammation, BPC-157 can alleviate underlying physiological stressors that often disrupt sleep architecture, such as those seen in restless legs syndrome or chronic pain-induced insomnia. Clinically, BPC-157 is often administered subcutaneously at doses between 200-500 mcg daily, typically for 2-4 week cycles. You'll observe that BPC-157 helps to restore physiological balance, thereby enhancing overall resilience and potentially reducing the intensity of some sleep-disrupting symptoms, leading to improved sleep onset and maintenance.

Growth hormone-releasing peptides (GHRPs) like Sermorelin and Ipamorelin, while primarily used to stimulate growth hormone release, can also indirectly improve sleep quality. Growth hormone is released in pulses during deep sleep, and enhancing its natural secretion can lead to more restorative sleep. These peptides work by stimulating the pituitary gland to release growth hormone, thereby supporting the body's natural sleep-wake cycles and recovery processes [7]. Sermorelin is typically dosed at 200-500 mcg subcutaneously before bedtime, while Ipamorelin is often used at 200 mcg subcutaneously before bedtime. You'll observe that these peptides contribute to a more profound and restful sleep by optimizing physiological repair processes, which are crucial for physical and mental restoration.

The nuance in utilizing peptides for sleep disorders lies in their ability to target specific neurobiological pathways that contribute to sleep disturbances, offering a more physiological approach compared to broad-acting sedatives. While traditional hypnotics often suppress brain activity globally, leading to fragmented sleep architecture and potential for dependence, peptides like DSIP appear to promote specific sleep stages, and ORAs specifically dampen wakefulness signals. GHRPs support the body's natural restorative processes during sleep, and BPC-157, by addressing systemic inflammation and gut-brain axis health, can alleviate secondary causes of sleep disorders. It's important to view these peptides as potential adjunctive treatments, working synergistically with established therapies like CBT-I or CPAP to provide more comprehensive and sustainable sleep improvement. They are not replacements for addressing underlying behavioral and psychological factors but rather complementary tools that can enhance sleep quality and promote long-term sleep health.

Comparing peptide interventions to conventional sleep aids, such as zolpidem (Ambien), reveals distinct mechanisms. Zolpidem acts rapidly to induce sleep but can lead to dependence and rebound insomnia upon discontinuation [8]. Peptides, conversely, aim to restore the body's intrinsic sleep-wake mechanisms, potentially offering a more physiological and less habit-forming solution. For a patient with chronic insomnia unresponsive to CBT-I and experiencing side effects from traditional hypnotics, consider an adjunctive trial of an orexin receptor antagonist, such as suvorexant 10 mg nightly, alongside ongoing CBT-I, to specifically target the wake-promoting system and improve sleep continuity without broad sedation. For sleep disturbances exacerbated by chronic pain or inflammation, BPC-157 at 250 mcg subcutaneously twice daily for 4 weeks could be considered to address the underlying physiological contributors to sleep disruption. Furthermore, for individuals with age-related decline in growth hormone and associated sleep fragmentation, Sermorelin at 300 mcg subcutaneously nightly could be a valuable addition to their treatment regimen.

References

[1] American Academy of Sleep Medicine. (2017). International Classification of Sleep Disorders – Third Edition (ICSD-3). Darien, IL: American Academy of Sleep Medicine.

[2] Saper, C. B., et al. (2005). The sleep switch: hypothalamic control of sleep and wakefulness. Trends in Neurosciences, 28(3), 152–158.

[3] Schneider-Helmert, D., & Schoenenberger, G. A. (1983). Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: A double-blind study. Neuropsychobiology, 9(4), 193–199.

[4] Muehlan, C., et al. (2023). The orexin story and orexin receptor antagonists for the treatment of insomnia. Journal of Sleep Research, 32(6), e13902.

[5] Monti, J. M., & Monti, D. (2007). Melanin-concentrating hormone and sleep. Sleep Medicine Reviews, 11(3), 197–205.

[6] Sikiric, P. C., et al. (2016). Brain-gut axis and pentadecapeptide BPC 157: Theoretical and practical implications. Current Pharmaceutical Design, 22(12), 1612–1621.

[7] Walker, R. F., et al. (1990). Growth hormone-releasing hormone (GHRH) and the sleep-wake cycle. Sleep, 13(1), 1–10.

[8] Sateia, M. J., et al. (2017). Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349.